

June 2026 Newsletter

Welcome to the ARLG Network's quarterly newsletter!

Thank you for supporting our mission to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

Read more for important ARLG updates, including:

- Program news, featuring a new ARLG Innovative Research Tools & Methods webpage
- Clinical site spotlight: UAB
- Member spotlights: Anthony Harris & Claudia Manca
- Events, featuring **ARLG Grand Rounds on Monday, June 8th**
- Study milestones
- New publications

News

Just Launched! ARLG Innovative Research Tools & Methods Webpage

Check out the new ARLG webpage featuring tools, methods, and research resources developed by ARLG to strengthen the design, conduct, and interpretation of clinical research focused on antimicrobial resistance (AMR).

[Read more](#)



ARLG DOTS and FAST Trials Featured in ESCMID Global Late-Breaking Session

The ARLG showcased its international impact on antibiotic resistance research at ESCMID Global 2026 with two multicenter trials, FAST and DOTS, featured in a late breaking session. The findings advance understanding of rapid diagnostics and long-acting antibiotics in the fight against AMR.



[Read more](#)

Congratulations, Emily Lydon, MD!

Congratulations to ARLG mentee Emily Lydon, MD, who received an Emerging Generation Award from the American Society for Clinical Investigation! This award recognizes Dr. Lydon for her important work to improve diagnostics for lower respiratory tract infections and prevent antibacterial resistance.



Emily Lydon, MD
Clinical Fellow
Dept. of Medicine, Division of
Infectious Diseases, UCSF

[Read more](#)

Congratulations, Ahmed Babiker, MBBS, MSc!

Congratulations to Ahmed Babiker, MBBS, MSc, ARLG Early Faculty Seedling Award recipient! His abstract, "Fecal microbiota transplantation results in durable long-term engraftment of donor-derived anaerobic taxa and MDRO decolonization," was selected as a Top Featured Oral Abstract at the Society for Healthcare Epidemiology of America (SHEA) Spring 2026 Conference. Only four abstracts receive this important distinction that recognizes research for its originality, scientific significance, methodological rigor, and potential to inform infection prevention practice.



Ahmed Babiker, MBBS, MSc
Assistant Professor, Dept.
of Internal Medicine, Division
of Infectious Diseases
Rush University

[Learn more about Babiker's work](#)

Clinical Site Spotlight



Todd McCarty, MD, University of Alabama at Birmingham (UAB)

Todd McCarty, MD, an Associate Professor and Infectious Diseases Fellowship Program Director at the University of Alabama at Birmingham (UAB), has been an active contributor to ARLG's antibacterial resistance research. His team has participated in the MDRO Network as well as key ARLG studies including the DOTS trial evaluating dalbavancin, CRACKLE, and multiple clinical trials on staphylococcal bacteremia and pneumonia.

Working within one of the nation's largest academic medical centers, Dr. McCarty collaborates with a multidisciplinary research team to advance studies in complex patient populations, particularly those who are immunocompromised or undergoing transplantation. He values ARLG's ability to bring together diverse sites to study less common but clinically significant infections, strengthening the impact and generalizability of research findings into antibacterial resistance.

[Read More](#)

ARLG Member Spotlights

Anthony Harris, MD, MPH

Anthony Harris, who specializes in research focused on antibiotic resistant bacteria, medical informatics, and healthcare epidemiology, has been passionate about antibiotic resistance for decades. He is also dedicated to preserving the future of antibiotic resistance research by helping young investigators.

Since he joined ARLG in 2014, he has led and served on the Mentoring Committee, which has granted more than 34 awards. During that time, he has mentored investigators who have received several ARLG awards including the [John G. Bartlett Fellowship](#), the [Early Faculty Seedling Award](#), and seed investigator awards. Through his own research and work to support and guide the next generation of AMR investigators, Dr. Harris advances ARLG's mission to impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

[Read more](#)



Anthony Harris, MD, MPH
Professor, University of
Maryland School of
Medicine

Claudia M.A. Manca, PhD

Please join us in congratulating Claudia M.A. Manca, PhD, on her retirement. At the Center for Discovery and Innovation at Hackensack Meridian Health, Dr. Manca managed and expanded the ARLG Virtual Biorepository and oversaw ARLG studies conducted there. Since ARLG's founding, she has played an important role in its growth as a global leader in the fight against antibiotic resistance.

Events



GRAND ROUNDS

Innovations in Diagnostic Trials

Monday, June 8th, 4-5 p.m. ET (Online)

Join us for the next ARLG Grand Rounds, **Innovations in Trial Designs**, moderated by Robin Patel, MD, D(ABMM), FIDSA, FACP, F(AAM), FAAAS.

- **Innovative Study Designs to Assess Test Performance**, presented by Michael Satlin, MD, Associate Professor of Medicine, Weill Cornell Medicine
- **Study Designs to Assess Impact of Diagnostics on Clinical Outcomes**, presented by Sarah Doernberg, MD, MAS, Professor of Medicine, University of California San Francisco
- **Lessons Learned from Recent Diagnostic Trials**, presented by Ritu Banerjee, MD, PhD, Professor, Pediatric Infectious Diseases, Vanderbilt University Medical Center

[Join the Grand Rounds on June 8th](#)

[View Grand Rounds Recordings](#)



ESCMID Global Abstracts Now Available

At ESCMID Global 2026, ARLG members shared their expertise in a late-breaking session about the ARLG DOTS and FAST trials and in several other sessions presented and co-chaired by members. Check out the [list of ARLG member sessions and posters](#) and download the abstract book on the [ESCMID Global website](#).



ESCMID Postgraduate Education Course

ARLG members Drs. Angela Huttner, David Paterson, and Tom Holland will join other experts to train the next generation of researchers in designing and conducting impactful clinical trials. The 3-day ESCMID postgraduate course will be held November 19-21 in Valleta, Malta.

[Learn more](#) and be sure to share this exciting opportunity with your mentees and others.

Study Milestones

STUDY NAME	ACRONYM ORIGIN	STATUS
FAST NCT06174649	Fast Antibiotic Susceptibility Testing for gram-negative bacteremia	Published
Innovations QoL (second study)	N/A	Manuscript Accepted

[Learn More about ARLG Studies](#)

New Publications

Banerjee R, Komarow L, Li Y, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. *JAMA*. Published online April 18, 2026. doi:[10.1001/jama.2026.5487](#)

Lodise TP, Turner NA, Hamasaki T, et al. Pharmacokinetics of Dalbavancin in Complicated *Staphylococcus aureus* Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial. *JAMA Netw Open*. 2026;9(4):e2611652. Published 2026 Apr 1. doi:[10.1001/jamanetworkopen.2026.11652](#)

Gottesdiener LS, Li Y, Greenwood-Quaintance KE, et al. Resistance to novel β -lactam/ β -lactamase inhibitors among carbapenem-resistant *Pseudomonas aeruginosa* and clinical implications in the prospective observational *Pseudomonas* study. *Antimicrob Agents Chemother*. Published online May 15, 2026. doi:[10.1128/aac.00388-25](#)


Kawai A, McElheny CL, Shields RK, et al. A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β -lactamase confers reduced susceptibility to advanced β -lactam agents, including cefiderocol. *mBio*. 2026;17(5):e0351825. doi:[10.1128/mbio.03518-25](#)

Mackow NA, Shao W, Ge L, et al. *Escherichia coli* ST131 Drives Carbapenem Use for *E. Coli* Bloodstream Infections. *Clin Infect Dis*. Published online March 6, 2026. doi:[10.1093/cid/ciag160](#)

Rodriguez-Temporal D, Gutiérrez-Pareja M, Gordy GG, Nahkala EM, Rodríguez-Sánchez B, Patel R. Prediction of KPC-producing *Klebsiella*

pneumoniae by MALDI-TOF MS, ensemble learning, and spectral peak annotation. *J Clin Microbiol.* 2026;64(5):e0146625. doi:[10.1128/jcm.01466-25](https://doi.org/10.1128/jcm.01466-25)

[View More ARLG Publications](#)



Duke Clinical Research Institute | 300 West Morgan Street Suite 800 | Durham, NC 27701 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)